Discover how Cellectis SA (CLLS) is advancing its CAR T therapies and securing financial stability through strategic partnerships and investments.

CEO Pascal Soriot emphasized that AstraZeneca's total revenue grew by ... Revenue growth in Q1 2025 was 10%, compared to 21% in Q4 2024. The gross margin improved slightly due to favorable FX.

Q1 2025 net product revenue for ZORYVE ® (roflumilast) was $63.8 million, a 196% increase compared to Q1 of 2024, and a 2% decrease compared to Q4 of 2024, due to typical first-quarter deductible ...

Q1 2025 net product revenue for ZORYVE® (roflumilast) was $63.8 million, a 196% increase compared to Q1 of 2024, and a 2% decrease compared to Q4 of 2024, due to typical first-quarter deductible reset ...

It is one of the best UK stocks to buy. Overall, 55 hedge funds were bullish on AstraZeneca PLC (NASDAQ:AZN) in Q4 2024, and it was part of 14 billionaire portfolios that had combined stakes worth ...

We recently published a list of 11 Best Performing Healthcare Stocks to Buy Now. In this article, we are going to take a look ...

Pfizer beats EPS estimates for the 12th quarter. Explore PFE's oncology success, cost-cutting impact, and why it's rated a ...

Best Pharma Stocks to Invest in Now. In this article, we are going to take a look at where AstraZeneca PLC (NASDAQ:AZN) ...

The latest quarterly results from a couple of major technology companies have soothed concerns about AI demand that prevailed ...